What are your top takeaways in Breast Cancer from ASCO 2022?
What were your “top 3” presentations/studies coming out of the meeting this year and how will it impact your own clinical practice?
12 Answers
Mednet MemberInvited Expert
Radiation Oncology · Varian Medical Systems/Allegheny health network
Answered on
- DESTINY-Breast04: it is phase III study of Trastuzumab deruxtecan (T-DXd) vs treatment of physician’s choice in HER2-low metastatic breast cancer (MBC). This study showed improved progression-free survival (PFS) and overall survival (OS) with T-DXd vs standard therapy in this patient population. T-...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Ohio State University Wexner Medical Center
Answered on
- DESTINY-Breast-04 is practice changing. In this study, the novel antibody-drug conjugate Trastuzumab deruxtecan outperformed physicians' choice of chemotherapy for patients with pretreated, metastatic HER2 low expressing breast cancer (IHC 1+ or IHC 2+ with negative FISH). There was a significant i...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Radiation Oncology · Beth Israel Deaconess Medical Center
Answered on
- Whelan T et al. LUMINA: A prospective trial omitting radiotherapy (RT) following breast conserving surgery (BCS) in T1N0 luminal A breast cancer (BC). (abstr LBA501) - The LUMINA single-arm prospective trial found that the local recurrence rate at 5 years was 2.3% following partial mastectomy and e...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Ohio State University
Answered on
- DESTINY-Breast04 - Takeaway: Clinically meaningful OS benefit and superior ORR over SOC chemotherapy in previously treated HER 2 low MBC (HER 2 IHC 1+ or 2+ with negative FISH) MBC. This makes TDxd a suitable treatment choice for a vast majority of patients with MBC independent of receptor subtype....
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of Texas MD Anderson Cancer Center
Answered on
- LBA3 - Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. One of the biggest benefits we have ever seen in HR+ disease where in late...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Medical College of Wisconsin
Answered on
- DESTINY-Breast04: which showed PFS benefit of Trastuzumab deruxtecan over traditional chemo in HER2 low positive (IHC +1, +2 but FISH negative) patients. This study expands the use of Trastuzumab deruxtecan to another 50% of patients who normally will not be offered an anti-HER2 therapy.
- MAINTAIN t...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Yale
Answered on
- DESTINY-Breast04 - We will have a new systemic therapy option for those with HER2 low disease which is urgently needed.
- LUMINA study - Important that we can possibly de-escalate radiation in patients 55 and older with luminal A tumors.
- KEYNOTE 522 and RCB analysis - Important additional analysis sh...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · University of North Carolina at Chapel Hill
Answered on
- DESTINY-Breast04: Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice in patients with HER2-low metastatic breast cancer. This is the first phase 3 trial of HER2-directed therapy in patients with HER2-low metastatic breast cancer to show a statistically significant and clinically ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Sarah Cannon Research Institute
Answered on
- DESTINY-Breast04 is quickly actionable. IHC was designed to identify the HER-2 high (IHC 3+) for trastuzumab. Was never for identifying 0 from 1+. A lot of variability here. Need to discuss 1+ as being actionable with our pathologists. Many I have talked to think that most tumors will have 1+ withi...
Join for free or sign in to see the full answer
Mednet Member
Medical Oncology · Washington University School of Medicine
Answered on
- DESTINY-Breast04 - TDxd clearly much better with impressive clinically relevant differences over TPC (capecitabine, eribulin, gemcitabine, taxane) in both ER+ and TNBC cohorts. Although the numbers with TNBC were small, the results were equally impressive in this cohort of 60 patients. Results are ...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · Washington University School of Medicine
Answered on
- Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study - The significant improvement in PFS and OS comparing T-DXd and SOC chemotherapy f...
Join for free or sign in to see the full answer
Mednet MemberInvited Expert
Medical Oncology · UT Health San Antonio
Answered on
- DESTINY-Breast04: the role of T-DXd in the treatment of HER2 low breast cancer: practice changing trial showing that patients with tumors Her2 1+ and 2+ can benefit from the use of T-DXd.
- TROPiCS-02: the role of sacituzumab govitecan in patients with metastatic ER+ breast cancer showing that this a...
Join for free or sign in to see the full answer